[Temporary Announcement] Yikang Pharmaceutical: Special report on the storage and use of raised funds
Announcement number: 2026-006
Securities code: 872799 Securities abbreviation: Yikang Pharmaceutical Sponsored securities firm: Shenwan Hongyuan underwriting and sponsoring
Shandong Yikang Pharmaceutical Co., Ltd.
Special report on the storage and use of raised funds
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
1. Basic information on raising funds
On March 16, 2020, the company held the seventh meeting of the third board of directors and reviewed and approved the "First Stock Issuance Plan for 2020". The proposal was reviewed and approved at the first extraordinary general meeting of shareholders in 2020. As confirmed by the National Equities Exchange and Quotations System’s “Letter on Share Registration for Stock Issuance of Shandong Yikang Pharmaceutical Co., Ltd.” (equity transfer system letter [2020] No. 947), the company issued 2,000,000 shares. The stock issuance price is RMB 5.5 per share, and the total amount of funds raised is RMB 11,000,000. The receipt of raised funds has been verified by Hexin Yanzi [2020] No. 000011 Capital Verification Report issued by Hexin Accounting Firm (Special General Partnership) on April 28, 2020.
2. Management of raised funds
In order to standardize the company's management of raised funds and improve the efficiency of the use of raised funds, the company has formulated a "Raised Funds Management System" in accordance with relevant regulations and requirements, implements special account storage and management of raised funds, and implements strict approval procedures for the use of raised funds to ensure that the funds are used exclusively.
In response to the company's first stock issuance in 2020, the company signed a "Tripartite Supervision Agreement on Raised Funds" (hereinafter referred to as the "Tripartite Supervision Agreement") with Shenwan Hongyuan Securities Underwriting and Sponsoring Co., Ltd. and Agricultural Bank of China Co., Ltd. The "Tripartite Supervision Agreement" complies with the "National Small and Medium Enterprises Equities Exchange and Quotations System Directed Issuance Rules" and other relevant regulations, and there are no problems with the performance of the three-party supervision agreement.
3. Actual use of funds raised during this reporting period
During the reporting period, there was no change in the use of raised funds, no use of raised funds to replace pre-invested self-raised funds, no use of idle raised funds for cash management, no use of idle raised funds to temporarily replenish working capital, and no transfer out of the balance of raised funds.
As of December 31, 2025, the uses and amounts of raised funds are as shown in the following table:
Item Amount (yuan)
Announcement number: 2026-006
Total raised funds 11,000,000.00 Issuance fee 0 Net raised funds 11,000,000.00 plus: interest income 39,069.04 plus: transfer 1,000.00 Specific purpose Cumulative amount of use Including: 2025
Raw and auxiliary material procurement costs 4,000,000.00 -
Drug research and development expenses 5,917,750.00 0.00
Handling fee 3,321.40 508.00 Balance of raised funds as of December 31, 2025 1,118,997.64
4. Problems in the use and disclosure of raised funds
During the reporting period, there was no irregularity in the management or use of raised funds, or untimely or inaccurate information disclosure.
5. Documents for reference
"Resolution of the Fifth Meeting of the Fifth Board of Directors of Shandong Yikang Pharmaceutical Co., Ltd.";
"Resolution of the Fifth Meeting of the Fifth Supervisory Board of Shandong Yikang Pharmaceutical Co., Ltd."
Board of Directors of Shandong Yikang Pharmaceutical Co., Ltd.
March 27, 2026